Dilsad Amanvermez Senarslan

Dilsad Amanvermez Senarslan

Auto-generated profile, based on publicly available information

Dilsad Amanvermez Senarslan

Department of Cardiovascular Surgery, Manisa Celal Bayar University, Faculty of Medicine, Manisa, Türkiye

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
DSDilsad Amanvermez Senarslan
Dilsad Amanvermez Senarslan
FYFunda Yildirim
Funda Yildirim
OTOmer Tetik
Omer Tetik

27 October 2008 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
HPHakan Posacioglu
Hakan Posacioglu
MAMehmet Fatih Ayik
Mehmet Fatih Ayik
MZMurat Zeytunlu
Murat Zeytunlu
DADilsad Amanvermez
Dilsad Amanvermez
CECagatay Engin
Cagatay Engin
AAAnil Ziya Apaydin
Anil Ziya Apaydin
Renal cell carcinoma extended to the right atrium was operated by using cardiopulmonary bypass and deep hypothermic circulatory arrest. Hypothermic circulatory arrest provides bloodless surgical field for tumor thrombus removal and adequate visceral and brain protection. The surgical technique that we used in a patient was reported in light of the literature.

1 October 2023 in Turkish Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
IÖİmGe Özdemir
İmGe Özdemir
TÖTülün Öztürk
Tülün Öztürk
DADilşad Amanvermez
Dilşad Amanvermez
FYFunda Yıldırım
Funda Yıldırım
AŞArife Şengel
Arife Şengel
IÖİbRahim Halil Özdemir
İbRahim Halil Özdemir
Background: This study aims to investigate the effects of goaldirected fluid therapy on the development of acute kidney injury in the perioperative period in patients undergoing cardiopulmonary bypass. Methods: Between November 2019 and May 2021, a total of 60 patients (46 males, 14 females; mean age: 62.5±9.6 years; range, 44 to 76 years) who were scheduled for elective coronary artery bypass grafting or valve surgery under cardiopulmonary bypass were included in the study. The patients were divided into two groups as the study group (Group S, n=30) and control group (Group C, n=30). The patients in Group C were treated with standard therapy, while the patients in Group S were treated with goal-directed fluid therapy. The Kidney Disease: Improving Global Outcomes (KDIGO) classification and renal biomarkers were used for the evaluation of acute kidney injury. Results: Acute kidney injury rates were similar in both groups (30%). Postoperative fluid requirement, intra-, and postoperative erythrocyte suspension requirements were significantly lower in Group S than Group C (p=0.002, p=0.02, and p=0.002, respectively). Cystatin-C was lower in Group S (p<0.002). The kidney injury molecule-1, glomerular filtration rate, and creatinine levels were similar in both groups. The length of hospital stay was longer in Group C than Group S (p<0.001). Conclusion: Although goal-directed fluid therapy does not change the incidence of acute kidney injury in patients undergoing cardiac surgery, it can significantly decrease Cystatin-C levels. Goal-directed fluid therapy can also decrease fluid and erythrocyte requirements with shorter length of hospital stay.

1 January 2023 in Sage Open Medicine
Verified
Journal Article
Open access
DSDilsad Amanvermez Senarslan
Dilsad Amanvermez Senarslan
FYFunda Yildırım
Funda Yildırım
BBBarıs Bayram
Barıs Bayram
AKAdnan Taner Kurdal
Adnan Taner Kurdal
OTOmer Tetik
Omer Tetik
Objectives: The current study aims to report midterm results of patients treated with endovascular intervention, kissing stent, or covered endovascular reconstruction of the aortic bifurcation, for Trans-Atlantic Inter-Society Consensus C or D aortoiliac occlusive disease involving the aortic bifurcation. Methods: Eighteen patients who have intermittent claudication or chronic limb threatening ischemia with Trans-Atlantic Inter-Society Consensus C or D aortoiliac occlusive disease involving the aortic bifurcation enrolled to the study between January 2018 and January 2021. Kissing stents, Advanta V12 (Atrium, Getinge Group), were used in 13 patients, and the covered endovascular reconstruction of the aortic bifurcation technique was used in 4 patients to reconstruct the aortic bifurcation. The patients were followed for a median of 49 months (min. 2, max.58 months). Patency rates, mortality, morbidities, and reinterventions were recorded. Results: The mean age of the patients was 60.4 ± 10 years. Technical success was achieved in 94.4% of the patients, but one patient had to convert to open surgery. Primary patency rate of the remaining patients was 85.6% at 58 months. Target lesion revascularization rate was 11.7%. One patient had successful reintervention for in stent restenosis, and secondary patency rate was 93.3% at 58 months. Limb salvage rate was 84.6% during the follow-up. Two patients had myocardial infarction (11.1%) and one mortality (5.6%) occurred because of cerebrovascular event in the follow-up. Conclusions: Endovascular techniques can be used safely for reconstruction of the aortic bifurcation in Trans-Atlantic Inter-Society Consensus C or D aortoiliac occlusive disease in selected patients who have high risk for open surgery. Covered endovascular reconstruction of the aortic bifurcation is the only technique that showed patency rates approaching open surgery in treatment of aortoiliac occlusive disease involving the aortic bifurcation to date. Although promising patency results were achieved with kissing-covered stents, long-term patency rates were still lower than those achieved with open surgery. Further randomized controlled studies comparing the long-term results of these techniques are needed.

1 September 2016 in International Journal of the Cardiovascular Academy
Verified
Journal Article
Open access
OSOmer Senarslan
Omer Senarslan
UKUmut Hasan Kantarci
Umut Hasan Kantarci
MEMehmet Eyuboglu
Mehmet Eyuboglu
DSDilsad Amanvermez Senarslan
Dilsad Amanvermez Senarslan
Primary and secondary cardiac tumors are a very rare entity, but secondary heart tumors are more common. Cardiac metastases occur in 10% all cancer patients. Hepatocellular carcinoma (HCC) is a very aggressive tumor. Intra-cardiac involvement with HCC rarely develops in a patient with HCC, and it has very poor prognosis. The clinical course of these patients may be complicated by many fatal cardiovascular complications. After the diagnosis of the heart involvement, median survival range is 1–4months. Early diagnosis of cardiac involvement is very important and its easy way is performing echocardiography. We describe here a rare case of a 65-year-old man with HCC that invaded the heart in 3 months

30 June 2021 in Perfusion
Verified
Journal Article
Closed access
PDF file
DSDilsad Amanvermez Senarslan
Dilsad Amanvermez Senarslan
FYFunda Yildirim
Funda Yildirim
AKAdnan Taner Kurdal
Adnan Taner Kurdal
ADAbdulkerim Damar
Abdulkerim Damar
TOTulun Ozturk
Tulun Ozturk
OTOmer Tetik
Omer Tetik
Introduction: A substantial amount of blood loss occurs during the open repair of aortic aneurysms or dissections. The aim of the present study is to determine the efficacy and cost-effectiveness of cell saver devices in blood conservation during the open repair of thoracic aortic pathologies. Methods: The present study prospectively collected the data pertaining to 25 patients who underwent surgical management of thoracic aortic aneurysms or dissections using a cell saver (Group 1, n = 25). The volume and cost of transfusion and postoperative outcomes were compared with the second group of patients who underwent surgery without the use of cell savers in the previous year (Group 2, n = 25); the data pertaining to the same were retrospectively collected from the hospital records. The patient characteristics and categorical variables were compared using the x2 test and Fisher’s exact test. Transfusion volume and costs were compared using the independent samples t-test and Mann–Whitney U test. Results: The patients in both the groups displayed similar characteristics and risk factors. The total volume of allogenic red blood cell (p < 0.001) and total blood product (p = 0.01) transfusions were significantly lower in Group 1. The cost of red blood cell (p < 0.001) and total transfusions (p = 0.03) were lower in Group 1. The two groups displayed similar in-hospital morbidity and mortality rates. Conclusions: There was a significant association between the use of cell savers and the decreased need for red blood cell and total blood product transfusions. Considering the cost of the cell saver set, transfusion costs in the two groups were comparable.